Tafenoquine and Beyond: CEO's Vision for the Future of 60 Degrees Pharmaceuticals

Learn about Sixty Degrees Pharma (Nasdaq: SXTP) from CEO Geoff Dow. In this exclusive overview, Dow provides insight into the company's mission to develop and commercialize new therapies for a range of infectious diseases, including its FDA-approved malaria preventative treatment ARAKODA® and the Company's current pipeline development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases. Learn more about this game-changing small-cap stock by visiting SXTPinfo.com today.